Global Next-Generation Antibody Therapeutics Market to Expand at 13% CAGR due to Latest Technological Advancements

Surging expenditure on healthcare, high incidence of chronic ailments, and greater R&D activities are the prominent factors that drive the demand for next-generation antibody therapeutics. Technological developments taking place in this field is also stimulating the growth of the global next-generation antibody therapeutics market.

Expanding at a CAGR of 13% from 2015 to 2022, the global next-generation antibody therapeutics market is estimated to reach US$2250 million by 2022, from US$6761.1 million in 2015. Better antibody therapeutics that ensure greater safety and delivery, and offer enhanced efficiency are known as next-generation antibody therapeutics. The problems associated with monoclonal bodies are not observed in next-generation antibody therapeutics.

Read Full Report: http://www.persistencemarketresearch.com/market-research/next-generation-antibody-therapeutics-market.asp

Moreover, next-generation antibody therapeutics possess enhanced features in addition to the existing features of therapeutic antibodies. Most biopharmaceutical and biotechnology companies are engaged in developing next-generation antibody therapeutics for inflammatory and autoimmune diseases, and cancer.

Biosimilar Antibody Products: A Rapidly Growing Segment

The global next-generation antibody therapeutics market is segmented on the basis of therapeutic area, technology, and geography. On the basis of therapeutic area, this market is categorized into inflammatory/autoimmune and oncology. The oncology segment is rapidly growing, and it holds the highest share in the global next-generation antibody therapeutics market within the therapeutic area segment.

Technology-wise, the global next-generation antibody therapeutics market is segmented into biosimilar antibody products, antibody fragments and antibody-like proteins, Fc engineered antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). The market for biosimilar antibody products is expanding at a rapid rate because of the low costs of biosimilar antibody products. High demand for biosimilar antibody products is mainly observed in low income economies of Eastern Europe, Latin America, and Asia Pacific.

There are several factors which have an adverse impact on the demand for next-generation antibody therapeutics, such as steep costs of next-generation antibody therapeutics, long approval times for new drugs, and stringent regulatory environment.

Adoption of Antibody-Drug Conjugates (ADC) Technology to Boost Market Demand

Geographically, the global next-generation antibody therapeutics market is segmented into Asia, North America, Europe, and Rest of the World. North America holds the highest share in the overall market for next-generation antibody therapeutics, with the U.S. contributing substantially to the revenue generated in this region. The robust growth of the U.S. next-generation antibody therapeutics market can be attributed to widespread R&D activities, high expenditure on healthcare, and high incidence of chronic diseases in the country.

The prominent companies in the global next-generation antibody therapeutics market are as follows: Dyax Corp., AstraZeneca, Takeda Pharmaceuticals Company Ltd., Xencor Inc., Bayer AG, Biogen, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, ImmunoGen Inc., Seattle Genetics Inc., Kyowa Hakko Kirin Co. Ltd., and F. Hoffmann-La Roche Ltd.

With the antibody-drug conjugates (ADC) technology gaining momentum, the global next-generation antibody therapeutics market is anticipated to witness several opportunities for further growth. Frequent business collaborations and business ventures is another factor that plays a vital role in simulating the demand for next-generation antibody therapeutics. It is also this factor that generated greater opportunities in the global next-generation antibody therapeutics market. The rising global expenditure on healthcare is acting as a driving force for consumers to shift their focus to next-generation antibody therapeutics.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s